- Many approved diabetes drugs and new obesity drugs have been shown to improve cardiometabolic risk factors; however, they have not been rigorously characterized in their cardiovascular profiles.
- The cardiovascular effects of novel compounds can be rigorously assessed in early phase development using advanced imaging and circulating and/or functional methodologies to inform development decisions based on early signs of cardiovascular risk or benefit.
- Robust characterization of the cardiovascular effects of a novel therapy during early development is a safe and cost-effective way to identify potential cardiovascular risk prior to initiating large, expensive phase 3 or 4 cardiovascular outcome trials.